Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
July 27, 2021
Assignee:
aTyr Pharma Inc.
Inventors:
Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
Abstract: The present disclosure relates to a polynucleotide having a novel promoter activity, a composition for expressing a gene comprising the polynucleotide, a microorganism comprising the gene, and a method for preparing purine nucleotides using the microorganism.
Type:
Grant
Filed:
April 8, 2019
Date of Patent:
June 22, 2021
Assignee:
CJ CHEILJEDANG CORPORATION
Inventors:
Min Ji Baek, Ji Hye Lee, So Jung Park, Jee Yeon Bae
Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
Abstract: The present invention provides for novel metabolic pathways to reduce or eliminate glycerol production and increase product formation. More specifically, the invention provides for a recombinant microorganism comprising a deletion of one or more native enzymes that function to produce glycerol and/or regulate glycerol synthesis and one or more native and/or heterologous enzymes that function in one or more engineered metabolic pathways to convert a carbohydrate source, such as lignocellulose, to a product, such as ethanol, wherein the one or more native and/or heterologous enzymes is activated, upregulated, or downregulated.
Abstract: Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
April 27, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Christina D. Smolke, Catherine Thodey, Isis Trenchard, Stephanie Galanie
Abstract: This document describes biochemical pathways for producing 7-aminoheptanoic acid using a ?-ketoacyl synthase or a ?-ketothiolase to form either a 5-amino-3-oxopentanoyl-[ACP] or 5-amino-3-oxopentanoyl-CoA intermediate. 7-aminoheptanoic acid can be enzymatically converted to pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol or the corresponding salts thereof. This document also describes recombinant microorganisms producing 7-aminoheptanoic acid as well as pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine and 1,7-heptanediol or the corresponding salts thereof.
Type:
Grant
Filed:
September 10, 2019
Date of Patent:
April 27, 2021
Assignee:
INV NYLON CHEMICALS AMERICAS, LLC
Inventors:
Alex Van Eck Conradie, Adriana Leonora Botes, Jonathan Kennedy, Nadia Fatma Kadi
Abstract: Described herein are engineered microalgae that exhibit enhanced lipid production during exponential growth. Such engineered microalgae are useful, for example, for the production of biofuels.
Abstract: Disclosed is a genetically modified host organism for expressing an anthracyclinone analogue. The genetically modified host organism comprises (i) synthetic nucleic acids; (ii) a biosynthetic pathway encoded by the synthetic nucleic acids, the (ii) biosynthetic pathway comprising a ketosynthase alpha, a ketosynthase beta/chain-length factor, an acyl carrier protein, a 3-oxoacyl-ACP synthase, a propionyl-CoA acyltransferase, a 9-ketoreductase, an aromatase/cyclase, and a second/third-ring cyclase; and (iii) a promoter positioned upstream of and operatively associated with the (ii) biosynthetic pathway. A method and corresponding synthetic nucleic acids are also disclosed.
Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
April 13, 2021
Assignee:
Codexis, Inc.
Inventors:
Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
Abstract: The present invention relates to processes for the preparation of sclareolide and related compounds by the biocatalytic cyclization of polyunsaturated carboxylic acid compounds, in particular of homofarnesylic acid and related compounds; and to a process for the preparation of ambroxide via the biocatalytic cyclization of homofarnesylic acid to sclareolide.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
March 23, 2021
Inventors:
Michael Breuer, Wolfgang Siegel, Stefan Ruedenauer, Ralf Pelzer
Abstract: Described are recombinant microorganisms characterized by having phosphoketolase activity, having a diminished or inactivated Embden-Meyerhof-Parnas pathway (EMPP) by inactivation of the gene(s) encoding phosphofructokinase or by reducing phosphofructokinase activity as compared to a non-modified microorganism and having a diminished or inactivated oxidative branch of the pentose phosphate pathway (PPP) by inactivation of the gene(s) encoding glucose-6-phosphate dehydrogenase or by reducing glucose-6-phosphate dehydrogenase activity as compared to a non-modified microorganism. These microorganisms can be used for the production of useful metabolites such as acetone, isobutene or propene.
Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
Type:
Grant
Filed:
October 15, 2019
Date of Patent:
March 9, 2021
Assignee:
Codexis, Inc.
Inventors:
Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
Abstract: Described is a recombinant expression vector that enables a cell transformed to contain and express the vector to use levulinic acid as a carbon source, thereby converting levulnic acid into 2-butanne. Also described are genetically modified cells transformed to contain and express the vector and methods of using the cells to produce 2-butanone from a medium containing levulinic acid.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
March 2, 2021
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Brian Frederick Pfleger, Jacqueline Marie Rand, Christopher Robert Mehrer, Matthew Ryan Incha
Abstract: The present invention relates to a nucleic acid molecule which encodes a polypeptide having cellulase activity and which is thermostable, wherein said nucleic acid molecule comprises or has a nucleotide sequence selected from: i) a nucleotide sequence which encodes an amino acid sequence as set forth in SEQ ID NO. 2 or as set forth in SEQ ID NO. 8; ii) a nucleotide sequence which encodes an amino acid sequence having at least 80% sequence identity to the amino acid sequence of (i); iii) a nucleotide sequence which encodes a part of the amino acid sequence of (i); iv) a nucleotide sequence which encodes a part of the amino acid sequence of (ii) wherein said part has at least 90% identity to an amino acid sequence of SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18 or SEQ ID NO. 20; v) a nucleotide sequence as set forth in SEQ ID NO. 1 or as set forth in SEQ ID NO.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
March 2, 2021
Assignee:
SINTEFF TTO AS
Inventors:
Alexander Wentzel, Anna Sofia Lewin, Mark Liles, Jinglie Zhou
Abstract: The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
Type:
Grant
Filed:
July 26, 2019
Date of Patent:
February 16, 2021
Assignee:
École Polytechnique Fédérale de Lausanne (EPFL)
Inventors:
Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
February 16, 2021
Assignee:
Research Development Foundation
Inventors:
Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung